Merck KGaA (MKKGY) – What Are Analysts Saying About This Stock?

Merck KGaA (OTCMKTS:MKKGY) has received a consensus recommendation of “Reduce” from the six analysts that are presently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation and five have issued a hold recommendation on the company.

A number of equities research analysts recently issued reports on the company. UBS Group lowered Merck KGaA from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 20th. Zacks Research downgraded Merck KGaA from a “hold” rating to a “strong sell” rating in a research report on Monday, October 12th.

Merck KGaA Stock Down 0.1%

MKKGY stock opened at $33.73 on Wednesday. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.69 and a quick ratio of 1.09. The company’s 50 day simple moving average is $31.68 and its 200-day simple moving average is $30.05. Merck KGaA has a 12 month low of $23.73 and a 12 month high of $34.19. The firm has a market capitalization of $21.80 billion, a PE ratio of 17.39, a P/E/G ratio of 2.93 and a beta of 0.92.

Merck KGaA Company Profile

Merck KGaA is a German science and technology company headquartered in Darmstadt. Founded in 1668, it traces its origins to a pharmacy established by the Merck family and has grown into a global business serving customers in healthcare, research and industry. It is separate from the U.S.-based Merck & Co. The company operates through three main businesses. Its Healthcare division develops and markets prescription medicines, including treatments in areas such as oncology, neurology and fertility.